The present invention provides: a compound (I) (in the formula: A is a pyridine ring, a furan ring, or the like； Y1 is an alkylene group having 1-6 carbon atoms； Y2 is a single bond or the like； R1 is -C(=O)-NH-SO2-R6, an acidic 5-membered heterocyclic group, or the like； R2 is a phenyl group that may have a substituent group, an aromatic heterocycle 5-membered ring that may have a substituent group, or the like； R3 is a halogen atom, an alkoxy group having 1-6 carbon atoms, or the like； R4 is a hydrogen atom, a halogen atom, or the like； R5 is a hydrogen atom or the like； and R6 represents an alkyl group having 1-6 carbon atoms, or the like) having EP1 receptor antagonism, and a pharmacologically acceptable salt thereof. Furthermore, the compound (I) can be used as a therapeutic drug or preventative drug for various symptoms of LUTS, particularly OABs.
